In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. (Q46428265)
Jump to navigation
Jump to search
scientific article published in June 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. |
scientific article published in June 2005 |
Statements
In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment (English)
Quesada AJ
Nelius T
Yap R
Zaichuk TA